David Zaccardelli, Verona Pharma CEO
August 10, 2022 10:02 AM EDTUpdated 10:26 AM
Financing

On heels of pos­i­tive COPD read­out, Verona to pro­vide new pub­lic of­fer­ing

Paul Schloesser

Associate Editor

Af­ter Verona Phar­ma’s COPD drug can­di­date proved to be ef­fec­tive in clin­i­cal tri­als and sent in­vestors scur­ry­ing to get in on the ac­tion, the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times